LYEL Lyell Immunopharma Inc Forecast, Technical & Fundamental Analysis
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors... Show more
LYEL is expected to report earnings to rise 94.55% to -214 cents per share on August 12
Q2'26
Est.
$-2.14
Q1'26
Missed
by $0.92
Q4'25
Missed
by $6.69
Q3'25
Missed
by $1.96
Q2'25
Missed
by $2.73
The last earnings report on May 06 showed earnings per share of -110 cents, missing the estimate of -18 cents. With 152.48K shares outstanding, the current market capitalization sits at 294.71M.
A.I.dvisor indicates that over the last year, LYEL has been loosely correlated with VCYT. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if LYEL jumps, then VCYT could also see price increases.
The Stochastic Oscillator for LYEL moved into oversold territory on June 22, 2026. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for LYEL's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Moving Average Convergence Divergence (MACD) for LYEL just turned positive on June 15, 2026. Looking at past instances where LYEL's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where LYEL advanced for three days, in of 243 cases, the price rose further within the following month. The odds of a continued upward trend are .
LYEL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 50-day moving average for LYEL moved below the 200-day moving average on May 29, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LYEL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for LYEL entered a downward trend on June 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. LYEL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.021) is normal, around the industry mean (20.966). P/E Ratio (0.000) is within average values for comparable stocks, (36.007). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.690). LYEL has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). LYEL's P/S Ratio (10000.000) is very high in comparison to the industry average of (367.026).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LYEL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
